Daniel Efiom-Ekaha MD, FACP.

Dedicated clinician, experienced leader with strong background in guiding teams, managing complex projects, and achieving strategic objectives. Excels in developing efficient processes, ensuring high standards, and aligning efforts with organizational goals. Known for collaborative approach and commitment to excellence.

• Diplomate, American Board of Internal Medicine. Board Certification in Internal Medicine.

• Diplomate, American Board of Internal Medicine. Board Certification in Hematology.

• Diplomate, American Board of Internal Medicine. Board Certification in Medical Oncology

• Diplomate American Board of Hospice and Palliative Medicine. Board Certified in Hospice and Palliative Medicine

• Royal College of Obstetricians and Gynecologists, London, UK. M.R.C.O.G. Part 1. 1999

• Targeted Oncology, Oncology Icons Award. 2023

• Resident of The Year, The Brooklyn Hospital Center. Brooklyn NY. 2001

• Intern of The Month, The Brooklyn Hospital Center. Brooklyn NY. 2000

• Nigerian Medical Association, Commendation for Original Research. 1995

• American Society of Clinical Oncology
• Fellow, American College of Physicians
• American Society of Hematology
• American Medical Association
• American Board of Internal Medicine

Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)

Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

Global Phase III Study to Assess the Effects of Durvalumab with Oleclumab or Durvalumab with Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9)

Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I)

Harbinger Health Collection of Blood and Tissue Samples from Cancer and NonCancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test

Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors

DNA evaluation of fragments for early interception - Lung Cancer  Training Study (DELFI-L101 Study)

Phase Ib/III Study of Capivasertib + CDK4/6 Inhibitors + Fulvestrant as Treatment for Advanced/Metastatic HR+/HER2-Breast Cancer (CAPItello-292)

An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects with Solid Tumors or Lymphoma

A Phase 3 OpenLabel, Randomized Study of Pirtobrutinib (LOXO-305) versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)

Tempus SCLC Observational Study: A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients with Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing Assays

Tempus GEMINI NSCLC Study: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Non-Small Cell Lung Cancer (NSCLC)

A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)

A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor A ctDNA Guided Early Switch Study

A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy

A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy

Daniel Efiom-Ekaha, A.G. Patel. Primary Peritoneal Cancer. Online book chapter eMedicine Journal, February 28 2003, VOLUME 4, Number 2

Daniel Efiom-Ekaha, A.G. Patel Hematopoietic stem Cell Transplantation. eMedicine Journal, October 13 2004, VOLUME 5, Number 10

A. S. Braverman, B. S. Kamenova, D. Efiom-Ekaha, C. Sohn; Brachial Plexus Syndrome in Breast Cancer Patients: A Complication of Locally Advanced or Recurrent Tumor. Proc Annu Meet Am soc Clin Oncol 2005; 23; 748.

Daniel Efiom-Ekaha, Joseph Feldman, Susan Gottesman, Natalya Krichmar, Olugbenga Olowokure, Jasotha Sanmugaharajah, Iuliana Shapira, William B Solomon, Emily Qian Chen. Infusional adriamycin based chemotherapy significantly improves the survival of Human T-cell Lymphotropic Virus-I Induced Acute Type Adult T-cell Leukemia Lymphoma. Accepted for Poster Presentation at the 2005 Annu Meet Am Soc Hem (abstract # 1484).

Boriana Kamenova · Albert S. Braverman. Michael Schwartz · Chul Sohn · Christopher Lange Daniel Efiom-Ekaha · Marvin Rotman · Harold Yoon Effective treatment of the brachial plexus syndrome in breast cancer patients by early detection and control of loco-regional metastases with radiation or systemic therapy. International Journal of Clinical Oncology Volume 14, Number 3  219-224

Daniel Efiom-Ekaha, M.D. Kelly Khai Li Yap, M.D.; Modified Bloom Richardson Score as a reliable predictor of breast cancer recurrence. Abstract presentation, 2011 Breast Cancer Symposium, San Francisco, Ca.

Daniel Efiom-Ekaha, M.D Kelly Khai Li Yap, M.D.; Obesity is not associated with increased recurrence risk in ER-positive breast cancer Abstract presentation, 2011 Breast Cancer Symposium, San Francisco, Ca.

Daniel Efiom-Ekaha, M.D Kelly Khai Li Yap, M.D.; Do younger women with early breast cancer have a higher recurrence risk? Abstract presentation, 2011 Breast Cancer Symposium, San Francisco, Ca

Daniel Efiom-Ekaha, M.D, Kelly Khai Li Yap, M.D.; Joseph Kannarkatt MD, McCormick, Timothy C MD. Ovarian and Thyroid Metastases from Renal Clear Cell Carcinoma (RCC) Successfully Treated with Metastectomy. Abstract presentation 2012 International Kidney Cancer Symposium.

L.M. de Souza-Lawrence, A.B. Shah, M. Young, F. Asrari, D.A. Frassica, V. Stearns, J. Werner, D.M. Efiom-Ekaha, A.C. Wolff, R.C. Zellars

Phase I/II Trial of Partial Breast Irradiation (PBI) With Various Concurrent Chemotherapy Regimens: Assessment of Skin Toxicity, Cosmetic Outcomes, and Disease Recurrence. International Journal of Radiation Oncology • Biology • Physics Volume 84, Issue 3, Supplement, Pages S219–S220, November 1, 2012

Taiho Oncology Speaker Bureau-LONSURF® + bevacizumab for the Treatment of 3L Metastatic Colorectal Cancer.

BeiGene Speaker Bureau- Discussion of Brukinsa for adult patients with CLL/SLL + 215

Boehringer Ingelheim Speaker Bureau- Gilotrif in NSCLCa

Dendreon Speaker Bureau- Adoption of Sipuleucel-T (Provenge) in Prostate Cancer.

Celgene Speaker Bureau- NabPaclitaxel in Pancreatic Cancer

Genomic Health Speaker-  Advanced Oncotype Dx in Breast Cancer

Norvatis Speaker Bureau- Everolimus in Multiple Malignancies. Oral iron Chelation with Exjade.

Lilly Oncology Speaker Bureau-Thoracic Oncology 

Millenium EPIC Speaker Bureau- Proteasome Inhibition in Cancer